MetaCap

BioNTech (BNTX) vs Qiagen N.V. (QGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Qiagen N.V. (QGEN) has outperformed BioNTech (BNTX) over the past year, gaining 5.3% versus a loss of 15.3%. Over five years, QGEN leads with a -15.4% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $10.18 billion), about 2.0 times the size.

Qiagen N.V. pays a dividend yielding 0.71%, while BioNTech does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTX-15.30%QGEN+5.25%
+28%-3%-33%
Nov 21, 20251 yearNov 20, 2026
BNTX-72.06%QGEN-13.86%
+25%-26%-77%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTX versus QGEN key metrics
MetricBNTXQGEN
Share price$80.96$49.30
Market cap$20.07B$10.18B
1-day change-0.52%-0.66%
YTD return-14.96%+9.63%
1-year return-15.30%+5.25%
5-year return-76.74%-15.40%
P/E ratio (TTM)—26.65
Forward P/E—18.48
EPS (TTM)$-6.83$1.85
Dividend yield0.00%0.71%
Annual dividend$0.00$0.35
Revenue (latest FY)—$2.09B
Revenue growth (YoY)—+5.65%
Net income (latest FY)—$424.88M
Gross margin—62.18%
Operating margin—22.29%
Net margin—20.33%
52-week high$124.00$57.82
52-week low$79.52$32.53
Distance from 52-week high-34.71%-14.74%
Analyst consensusbuyhold
Avg. price target upside+38.51%+0.95%
Average volume1.08M3.65M
Shares outstanding247.93M206.50M
Employees7,8075,400
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QGEN has outperformed BNTX by 20.6 percentage points over the past year.

About BioNTech

BNTX stock →

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees

About Qiagen N.V.

QGEN stock →

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,400 employees

BNTX vs QGEN FAQ

Which is bigger, BioNTech or Qiagen N.V.?

BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $10.18B for Qiagen N.V. (QGEN).

Which stock has performed better over the past year, BNTX or QGEN?

QGEN returned +5.25% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, BioNTech or Qiagen N.V.?

Qiagen N.V. pays a dividend yielding 0.71%, while BioNTech does not currently pay a regular dividend.

Are BioNTech and Qiagen N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons